329 results on '"Ramnath N"'
Search Results
2. P2.09-15 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
3. Symptomatic Pneumonitis Rates Among Patients with Stage III Non-Small Cell Lung Cancer Receiving Adjuvant Durvalumab
4. Efficiency Effectiveness Gap of Durvalumab in Locally Advanced Non-Small Cell Lung Cancer
5. Wood dust exposure and the risk of upper aero-digestive and respiratory cancers in males
6. Real-Time Surveillance of New Anticancer Therapies in the National Veterans Affairs System
7. P57.03 Cellular Engagement and Interaction in the Tumor Microenvironment (TME) Predicts Response to ICI in Metastatic NSCLC
8. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
9. P21.09 Does Duration of Maintenance Durvalumab Matter? Relationship between Length of Durvalumab Therapy and PFS.
10. P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome
11. Stress-strain behavior of steel fiber-reinforced concrete in compression
12. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
13. S-phase modulation by irinotecan: pilot studies in advanced solid tumors
14. P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study
15. Retinoids and apoptosis in cancer therapy
16. A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors: 3171
17. Predictors of Post-Treatment Hospitalization in Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SBRT) for Centrally Located Tumors
18. FDG PET-CT Quantitative Features Predict Immune Checkpoint Blockade Efficacy
19. Predictors of Long-Term Survival Among Locally Advanced Non–small Cell Lung Cancer Patients Undergoing Definitive Radiation Therapy
20. Clinical Predictors of Durable Clinical Benefit of Pembrolizumab Therapy in Veterans With Metastatic Non–Small Cell Lung Cancer
21. A Phase II Trial of Midtreatment PET-CT Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer (NSCLC)
22. Fibulin-4 deficiency increases TGF-β signalling in aortic smooth muscle cells due to elevated TGF-β2 levels
23. Durability of Dual Clutch Transmission Fluids
24. New Durability Testing of Dual Clutch Transmission Fluids
25. Developing Transmission Fluids with Enhanced Durability
26. Enhanced Stability of Transmission Clutch Engagement with Temperature-Dependent ATF Friction
27. Investigation of Pitting Mechanism in the FZG Pitting Test
28. CVT Fluid Development: Investigations of Friction Durability and Wear in a Push-belt Variator
29. Concurrent Carboplatin, Paclitaxel, and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase 2 Multicenter Trial
30. A Phase 2 Trial of Midtreatment FDG-PET Adaptive, Individualized Radiation Therapy Plus Concurrent Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
31. Comparing a CVT to a Four-speed Automatic Transmission on Stress to the ATF
32. Personalized High Dose Radiation (>70 Gy) Is Significantly Associated with Better Local Regional Control and Overall Survival in Non-small Cell Lung Cancer Treated with Concurrent Chemoradiation
33. Re-irradiation May be a Viable Option for Patients with Local Recurrence after a Definitive Course of Radiation Therapy in Non-small Cell Lung Cancer
34. Can We Deliver High Dose Radiation in 6 Weeks with Concurrent Chemotherapy in Stage III Non-small Cell Lung Cancer?
35. Concurrent Chemoradiotherapy Increases the Risk of Radiation-Induced Pericardial Effusion in Patients with Locally Advanced Non-small Cell Lung Cancer
36. Use of increase in esophageal FDG SUV during radiotherapy to predict radiation esophagitis.
37. Evaluation of CYP24A1 mRNA expression as a prognostic marker and predictor of calcitriol activity in lung adenocarcinoma.
38. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies.
39. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC).
40. The Additional Value of V/Q SPECT over Q SPECT Alone for Pulmonary Function Mapping before, during and after Radiotherapy in Patients with Non–small Cell Lung Cancer
41. Durability of Dual Clutch Transmission Fluids
42. Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801
43. Pulmonary functional map on V/Q SPECT and TGFβ1 during radiotherapy and post-treatment lung function in patients with non-small cell lung cancer
44. New Durability Testing of Dual Clutch Transmission Fluids
45. Erlotinib for metastatic non-small cell lung cancer (mNSCLC): First, second or third line setting—Does it matter? A single institution experience
46. Developing Transmission Fluids with Enhanced Durability
47. A single institution experience with neuroendocrine tumors
48. Hormone Replacement Therapy as a Risk Factor for Non-Small Cell Lung Cancer: Results of a Case-Control Study
49. 381 POSTER HSP27 as a novel target in Non-small cell lung cancer with particular implications for migration and metastasis
50. 2458
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.